131 related articles for article (PubMed ID: 24138224)
1. An update on the pharmacotherapy for endometrial cancer.
Amadio G; Masciullo V; Stefano L; Scambia G
Expert Opin Pharmacother; 2013 Dec; 14(18):2501-9. PubMed ID: 24138224
[TBL] [Abstract][Full Text] [Related]
2. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report.
Price FV; Edwards RP; Kelley JL; Kunschner AJ; Hart LA
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-78-S15-82. PubMed ID: 9346228
[TBL] [Abstract][Full Text] [Related]
3. Current treatment options for endometrial cancer.
Santin AD; Bellone S; O'Brien TJ; Pecorelli S; Cannon MJ; Roman JJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):679-89. PubMed ID: 15270671
[TBL] [Abstract][Full Text] [Related]
4. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
5. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.
Sehouli J; Koensgen D; Oskay-Ozcelik G; Mustea A
Crit Rev Oncol Hematol; 2008 Sep; 67(3):204-12. PubMed ID: 18407513
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.
Karagol H; Saip P; Uygun K; Kucucuk S; Aydiner A; Topuz E
Med Oncol; 2006; 23(4):543-8. PubMed ID: 17303913
[TBL] [Abstract][Full Text] [Related]
9. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
Simpkins F; Drake R; Escobar PF; Nutter B; Rasool N; Rose PG
Gynecol Oncol; 2015 Feb; 136(2):240-5. PubMed ID: 25485782
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for high-risk early-stage endometrial cancer.
Kodama J; Seki N; Hiramatsu Y
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):42-7. PubMed ID: 17218851
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study.
Bevis KS; Kilgore LC; Alvarez RD; Straughn JM; Leath CA
J Reprod Med; 2014; 59(3-4):113-20. PubMed ID: 24724218
[TBL] [Abstract][Full Text] [Related]
13. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
Moore KN; Tian C; McMeekin DS; Thigpen JT; Randall ME; Gallion HH
Cancer; 2010 Dec; 116(23):5407-14. PubMed ID: 20737572
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
[TBL] [Abstract][Full Text] [Related]
15. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer.
Obata H; Aoki Y; Watanabe M; Matsushita H; Yahata T; Fujita K; Kurata H; Tanaka K
Int J Clin Oncol; 2003 Feb; 8(1):53-5. PubMed ID: 12601544
[TBL] [Abstract][Full Text] [Related]
17. Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.
Lu SM; Chang-Halpenny C; Hwang-Graziano J
Gynecol Oncol; 2015 Apr; 137(1):28-33. PubMed ID: 25666606
[TBL] [Abstract][Full Text] [Related]
18. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
19. [Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer].
Misawa A; Nagao M; Kushimoto T; Yasuda M
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1901-5. PubMed ID: 19011339
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
Hogberg T
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
